|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Extraction of indole alkaloids from Tabernaemontana catharinensis using supercritical CO2+ethanol:an evaluation of the process variables and the raw material origin显示文摘 | CAMILA G P MARCIA O M M ALAIDE S B | 2004 | J Supercrit Fluids2004，30，： | 1 |
| 2 | Transesterification of soybean oil catalyzed by sulfated zirconia 显示文摘 | CAMILA M G SERGIO T LETICIA L M | 2008 | Bioresour Technol2008，99，： | 1 |
| 3 | Collection and recycling of electronic scrap: a worldwide overview and comparison with the Brazilian situation显示文摘 | CAMILA R O ANDRIA M B ANNELISE E G | 2012 | Waste Manage- ment2012，32，8： | 1 |
| 4 | Metabolic disease and the liver: A review显示文摘Metabolic dysfunction-associated steatotic liver disease(MASLD)is the most common liver disease worldwide,with an estimated prevalence of 31%in Latin America.The presence of metabolic comorbidities coexisting with liver disease varies substantially among populations.It is acknowledged that obesity is boosting the type 2 diabetes mellitus“epidemic,”and both conditions are significant contributors to the increasing number of patients with MASLD.Nonalcoholic steatohepatitis represents a condition of chronic liver inflammation and is considered the most severe form of MASLD.MASLD diagnosis is based on the presence of steatosis,noninvasive scores and altered liver tests.Noninvasive scores of liver fibrosis,such as serum biomarkers,which should be used in primary care to rule out advanced fibrosis,are simple,inexpensive,and widely available.Currently,guidelines from international hepatology societies recommend using noninvasive strategies to simplify case finding and management of high-risk patients with MASLD in clinical practice.Unfortunately,there is no definite pharmacological treatment for the condition.Creating public health policies to treat patients with risk factors for MASLD prevention is essential. | Márcia Vargas Sheila de Castro Cardoso Toniasso Patricia G Riedel Camila Pereira Baldin Francielle Lopes dos Reis Robson Martins Pereira Maria Carlota Borba Brum Dvora Joveleviths Mario Reis Alvares-da-Silva | 2024 | World Journal of Hepatology2024，16，1： | 0 |
| 5 | Oncologic aspects of the decision-making process for surgical approach for colorectal liver metastases progressing during chemotherapy显示文摘Colorectal cancer represents the third most diagnosed malignancy in the world.The liver is the main site of metastatic disease,affected in 30%of patients with newly diagnosed disease.Complete resection is considered the only potentially curative treatment for colorectal liver metastasis(CRLM),with a 5-year survival rate ranging from 35%to 58%.However,up to 80%of patients have initially unresectable disease,due to extrahepatic disease or bilobar multiple liver nodules.The availability of increasingly effective systemic chemotherapy has contributed to converting patients with initially unresectable liver metastases to resectable disease,improving long-term outcomes,and accessing tumor biology.In recent years,response to preoperative systemic chemotherapy before liver resection has been established as a major prognostic factor.Some studies have demonstrated that patients with regression of hepatic metastases while on chemotherapy have improved outcomes when compared to patients with stabilization or progression of the disease.Even if disease progression during chemotherapy represents an independent negative prognostic factor,some patients may still benefit from surgery,given the role of this modality as the main treatment with curative intent for patients with CRLM.In selected cases,based on size,the number of lesions,and tumor markers,surgery may be offered despite the less favorable prognosis and as an option for non-chemo responders. | Raphael L C Araujo Camila G C Y Carvalho Carlos T Maeda Jean Michel Milani Diogo G Bugano Pedro Henrique Z de Moraes Marcelo M Linhares | 2022 | World Journal of Gastrointestinal Surgery2022，14，9： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员